Huons Co., Ltd. (CEO Ki-an Eom) confirmed the inhibitory effect against the Corona 19 (COVID-19) virus in a cell test of’Zephirus (ingredient names budesonide, salmeterol), which is being developed as a COVID-19 treatment through drug re-creation It was revealed on the 17th.
In a cell (in-vitro) test, Huons confirmed the decrease in viral gene expression by Zephyrus in human lung epithelial cell lines infected with the’COVID-19 GH type mutant virus’, which is the most widely distributed in Korea. In particular, it was confirmed that the virus inhibitory effect was increased by up to 39% when Zephyrus treatment was compared to budesonide single treatment, and cytotoxicity was not observed.
Researchers at Oxford University in the UK recently revealed the results of a study that budesonide, a treatment for asthma, lowers the hospitalization rate and recovery rate of COVID-19 patients. In addition, in the cell test of Zephyrus, a combination drug of budesonide and salmeterol, the fact that the virus suppression effect was significantly increased is eye-catching.
Reporter So Min-hee news114 @newsrun.co.kr